TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
Clinical trial NCT06961786 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06961786
- Sponsor
- TILT Biotherapeutics Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-25
- Primary completion
- 2026-11-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.